Targeting influenza virosomes to ovarian carcinoma cells

Mastrobattista, Enrico; Schoen, Pieter; Wilschut, Jan; Crommelin, Daan J.A.; Storm, Gert

doi:10.1016/s0014-5793(01)03112-x

Cited by 27 publications

(13 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A similar inhibition of hemagglutination was seen after anchoring polyethylene glycol (PEG) chains on the surface of influenza virosomes. 24 Alternatively, dilution of the HN with the OMPs on the…”

Section: Discussionmentioning

confidence: 99%

Untitled

Homhuan¹,

Pathanasophon²,

Crommelin³

et al. 2004

ScienceAsia

View full text Add to dashboard Cite

Pasteurella multocida, a gram-negative bacterium, is the causative agent of fowl cholera and other diseases of wild and production animals.1 Based on epidemiological information collected in Thailand, strains of serogroup A are recognized as the primary cause of fowl cholera, whereas isolates of serogroups B, D and F are less frequently associated with disease. 2Vaccination is the most attractive approach for controlling the disease. Two types of vaccine against P. multocida are currently being used for immunization of poultry: attenuated and inactivated vaccines. Recently, the development of subunit vaccines comprising purified subunits of this microorganism has been promoted. Outer membrane proteins (OMPs) from P. multocida have been isolated. They provided various degrees of protection against a challenge. 3-6Apart from the discovery and selection of potent immunogens, a key factor to the success of vaccine development is proper delivery of the immunogens to the immune system. 7 To date, there are no data available in the literature on the role of antigen delivery systems for OMPs of P. multocida on vaccine efficacy. This ABSTRACT: Fowl cholera is an infectious disease affecting poultry and is caused by Pasteurella multocida. To develop a subunit vaccine, outer membrane proteins (OMPs) from P. multocida serotype A:1 strain NIAH DU1551/97 were extracted and characterized using SDS-PAGE. The OMPs were solubilized in detergent or incorporated in lipid-based antigen delivery systems, namely virosomes made from Newcastle disease (ND) virus and immunostimulating complexes (ISCOMs). The formulations were characterized by several physicochemical methods. To evaluate the formulations as possible vaccine, their potency was tested in mice. Eleven proteins that range in size from 30 to 80 kDa were detected in the OMP fraction. The most prominent protein bands were 30, 33, and 45 kDa. Virosomes and ISCOMs showed an average diameter of 180 and 30 nm, respectively. OMPs incorporated in the virosomal membrane inhibited the capability of virosomes to agglutinate chicken red blood cells. Animals were challenged after two immunizations. All vaccines fully protected mice against a low dose challenge. In the case of a high dose challenge, micellar OMPs provided 80% protection, whereas OMPs incorporated in virosomes or ISCOMs gave 100% protection, which is comparable to that of inactivated whole cell vaccines. In conclusion, antigen loaded virosomes and ISCOMs are potential pasteurella subunit vaccines.

show abstract

Section: Discussionmentioning

confidence: 99%

Untitled

Homhuan¹,

Pathanasophon²,

Crommelin³

et al. 2004

ScienceAsia

View full text Add to dashboard Cite

show abstract

“…More importantly, to achieve a target selecting ability, targeting molecules (such as antibodies) can be conjugated to these hydrophilic polymers and inserted into the membrane of virosomes (40,41).…”

Section: Optimization Of Virosomesmentioning

confidence: 99%

Virosome, a hybrid vehicle for efficient and safe drug delivery and its emerging application in cancer treatment

Liu

Feng

et al. 2015

Acta Pharmaceutica

View full text Add to dashboard Cite

A virosome is an innovative hybrid drug delivery system with advantages of both viral and non-viral vectors. Studies have shown that a virosome can carry various biologically active molecules, such as nucleic acids, peptides, proteins and small organic molecules. Targeted drug delivery using virosome-based systems can be achieved through surface modifi cations of virosomes. A number of virosome--based prophylactic and therapeutic products with high safety profi les are currently available in the market. Cancer treatment is a big ba lefi eld for virosome-based drug delivery systems. This review provides an overview of the general concept, preparation procedures, working mechanisms, preclinical studies and clinical applications of virosomes in cancer treatment.

show abstract

“…Due to the ubiquitous nature of the cell surface receptors targeted by HA, directing virosomes to a specific cell type is challenging because they must be redirected and targeted concurrently. By coupling Fab′ fragments of an anti-epithelial glycoprotein antibody to the distal end of PEG, reconstituted virosomes have been shown to selectively target ovarian carcinoma cells (102). In this instance, the conjoined antibody ensures target cell specificity.…”

Section: Pseudovirions As a Class Of Delivery Vehiclesmentioning

confidence: 99%

Pseudovirions as Vehicles for the Delivery of siRNA

et al. 2009

View full text Add to dashboard Cite

Over the last two decades, small interfering RNA (siRNA)-mediated gene silencing has quickly become one of the most powerful techniques used to study gene function in vitro and a promising area for new therapeutics. Delivery remains a significant impediment to realizing the therapeutic potential of siRNA, a problem that is also tied to immunogenicity and toxicity. Numerous delivery vehicles have been developed including some that can be categorized as pseudovirions: these are vectors that are directly derived from viruses but whose viral coding sequences have been eliminated, preventing their classification as viral vectors. Characteristics of the pseudovirions discussed in this review, namely phagemids, HSV amplicons, SV40 in vitro-packaged vectors, influenza virosomes, and HVJ-Envelope vectors, make them attractive for the delivery of siRNA-based therapeutics. Pseudovirions were shown to deliver siRNA effector molecules and bring about RNA interference (RNAi) in various cell types in vitro, and in vivo using immune-deficient and immune-competent mouse models. Levels of silencing were not always determined directly, but the duration of siRNAinduced knockdown lasted at least 3 days. We present examples of the use of pseudovirions for the delivery of synthetic siRNA as well as the delivery and expression of DNA-directed siRNA.

show abstract

Targeting influenza virosomes to ovarian carcinoma cells

Cited by 27 publications

References 42 publications

Untitled

Untitled

Virosome, a hybrid vehicle for efficient and safe drug delivery and its emerging application in cancer treatment

Pseudovirions as Vehicles for the Delivery of siRNA

Contact Info

Product

Resources

About